版本:
中国

BRIEF-Blueprint Medicines announces Proof-of-Concept Data from Global Phase 1 clinical trial of BLU-554 in patients with advanced Hepatocellular Carcinoma

Nov 28 Blueprint Medicines Corp

* Blueprint Medicines announces proof-of-concept data from global phase 1 clinical trial of BLU-554 in patients with advanced Hepatocellular Carcinoma

* Blueprint Medicines Corp says radiographic tumor reduction observed in 5 of 10 patients with FGFR4 pathway activation Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐